Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115651 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Zichen Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Oral Diseases, Department of Stomatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang Unive…. Hauptthemen laut MEDLINE: Cisplatin, Naphthoquinones, Tongue Neoplasms, Kruppel-Like Transcription Factors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: State Administration of Traditional Chinese Medicine of the People's Republic of China, Second Affiliated Hospital of Soochow University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Tongue squamous cell carcinoma (TSCC) is a therapeutic challenge due to frequent cisplatin resistance and an immunosuppressive tumor immune microenvironment (TIME). Effective strategies must address both barriers. We evaluated the antitumor effects of plumbagin (PLB) in cisplatin-sensitive and -resistant TSCC cells, as well as in xenograft, patient-derived xenograft, and humanized mouse models. PLB downregulated ZWINT and inhibited NF-κB signaling, thereby restoring cisplatin sensitivity in resistant cells. In vivo, PLB significantly suppressed tumor growth and enhanced cisplatin efficacy. Mechanistically, PLB stabilized KLF2, promoting JAK1/STAT2 signaling, TIME remodeling, and partial restoration of CD8+ T-cell function. These dual actions-tumor chemosensitization via ZWINT/NF-κB inhibition and immune reprogramming via KLF2 activation-were functionally interconnected, as cytokines released by PLB-primed T cells reinforced NF-κB suppression in tumor cells. Collectively, our findings identify PLB as a low-cost small molecule that integrates cisplatin sensitization with immune activation, offering a promising adjunctive strategy for cisplatin-refractory TSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Oral Diseases, Department of Stomatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Department of Stomatology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
- Jiangxi Provincial Key Laboratory of Oral Diseases, Department of Stomatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China; Postdoctoral Innovation Practice Base…
- Postdoctoral Innovation Practice Base, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China; Jiangxi Provincial Key Laboratory of Urinary System Diseases, Department of Urology, T…
- Jiangxi Provincial Key Laboratory of Oral Diseases, Department of Stomatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. Electronic address: xqiujiaxuan@163.c…
Förderung
- State Administration of Traditional Chinese Medicine of the People's Republic of China
- Second Affiliated Hospital of Soochow University
- National Natural Science Foundation of China
Zitieren
APA
Xu, Z., Xin, Y., Jiang, Q., Zhang, X., Liu, Y., Zou, R., Zhou, L., Xue, D., & Qiu, J. (2025). Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115651
Vancouver
Xu Z, Xin Y, Jiang Q, Zhang X, Liu Y, Zou R, et al. Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115651
BibTeX
@article{Xu2025,
author = {Xu, Zichen and Xin, Yuqi and Jiang, Qingkun and Zhang, Xinjian and Liu, Yang and Zou, Ruiyang and Zhou, Lizhi and Xue, Danfeng and Qiu, Jiaxuan},
title = {Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115651}
}
EUVIMED